Seila Lorenzo-Herrero

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 5

Top Topics

Combination Therapy

Immune Response

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Seila Lorenzo-Herrero, Christian Sordo-Bahamonde, Alejandra Martínez-Pérez, María Daniela Corte-Torres, Ivan Fernandez-Vega, Mª Pilar Solís-Hernández, Segundo González
Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma. Cancer science (2022)
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana Pilar Gonzalez-Rodriguez, Ángel R Payer, Esther González-García, Alejandro López-Soto, Segundo González
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers 13 (9) (2021)
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana Pilar Gonzalez-Rodriguez, Ángel R Payer, Esther González-García, Alejandro López-Soto, Segundo González
BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. Cancers 13 (8) (2021)
Marco H Hofmann, Rajeswaran Mani, Harald Engelhardt, Maria A Impagnatiello, Sebastian Carotta, Marc Kerenyi, Seila Lorenzo-Herrero, Jark Böttcher, Dirk Scharn, Heribert Arnhof, Andreas Zoephel, Renate Schnitzer, Thomas Gerstberger, Michael P Sanderson, Girish Rajgolikar, Swagata Goswami, Sumithira Vasu, Peter Ettmayer, Segundo González, Mark Pearson, Darryl B McConnell, Norbert Kraut, Natarajan Muthusamy, Jürgen Moll
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance. Molecular cancer therapeutics 19 (4) (2020)
Christian Sordo-Bahamonde, Massimo Vitale, Seila Lorenzo-Herrero, Alejandro López-Soto, Segundo González
Mechanisms of Resistance to NK Cell Immunotherapy. Cancers 12 (4) (2020)